FibroGen, Inc. (FGEN)

$11.4

+0.84 (+7.95%)
Rating:
Recommendation:
Neutral
Symbol FGEN
Price $11.4
Beta 0.897
Volume Avg. 0.98M
Market Cap 1.064B
Shares () -
52 Week Range 7.81-27.55
1y Target Est -
DCF Unlevered FGEN DCF ->
DCF Levered FGEN LDCF ->
ROE -118.07% Strong Sell
ROA -37.73% Strong Sell
Operating Margin -
Debt / Equity 359.33% Strong Buy
P/E -
P/B 6.71 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest FGEN news


Mr. Enrique Conterno
Healthcare
Biotechnology
NASDAQ Global Select

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.